Library / regulatory-reference
Uzbekistan: Agency for Development of the Pharmaceutical Industry
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The Agency for Development of the Pharmaceutical Industry, operating under the Ministry of Health of the Republic of Uzbekistan, is the country's national body for medicines regulation and pharmaceutical-sector development.
Uzbekistan is Central Asia's most populous market, and the agency's dual mandate, combining registration and oversight with industrial development, reflects a national policy of building domestic production alongside imports.
How products enter the market
Medicines require state registration after evaluation of quality, safety and efficacy, and manufacturers, importers and distributors operate under licensing and good-practice requirements that have been progressively tightened toward international norms.
Post-market supervision covers quality control, safety monitoring and enforcement against substandard and falsified products.
Regional and international role
The agency's development mandate makes Uzbekistan a closely watched case in Central Asia: regulatory modernization is being used deliberately to attract manufacturing investment and align with international standards.
Regional cooperation includes work with neighboring Central Asian regulators and participation in broader Eurasian harmonization discussions.
Using this profile
The agency publishes regulatory acts, draft guidance and announcements in Uzbek, Russian and English through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: Uzbekistan illustrates the regulator-developer hybrid: an agency that both polices the market and carries the industrial-policy goal of growing domestic production.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.